Want to see HK:2487 full AI Analyst Report?
Top Page
Cutia Therapeutics
(2487)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$0.67
▼(-85.42% Downside)
Action:Reiterated
Date:10/17/26
The score is primarily constrained by weak financial quality—large operating losses and ongoing negative free cash flow—despite improved revenue growth and solid gross margins. Technicals further weigh on the score as the price remains well below key moving averages with bearish momentum, while valuation signals are limited due to negative earnings and no dividend data.
Positive Factors
Revenue Growth
The sharp improvement in revenue growth indicates stronger commercial traction than in the prior year and can expand the company’s operating base over the next several quarters. Sustained growth would improve the potential to absorb fixed research and development costs.
Negative Factors
Persistent Operating Losses
The scale of operating and net losses shows that Cutia remains far from break-even despite stronger revenue growth. Continued losses can consume capital, limit strategic flexibility, and delay the point at which the company can fund expansion through internally generated earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The sharp improvement in revenue growth indicates stronger commercial traction than in the prior year and can expand the company’s operating base over the next several quarters. Sustained growth would improve the potential to absorb fixed research and development costs.
Read all positive factors
Cutia Therapeutics (2487) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$259.84M
Dividend YieldN/A
Average Volume (3M)923.61K
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue Growth35.47%
EPS Growth46.42%
CountryHK
Employees268
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.79
Shares Outstanding376,583,700
10 Day Avg. Volume426,920
30 Day Avg. Volume923,606
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.52
Price to Sales (P/S)4.01
P/FCF Ratio-4.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)HK$580.00M
Cutia Therapeutics Business Overview & Revenue Model
Company Description
Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, ...
Cutia Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
55
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 332.64M | 336.15M | 279.62M | 137.62M | 11.37M | 2.04M |
| Gross Profit | 178.26M | 195.79M | 143.46M | 71.01M | 7.94M | 1.61M |
| EBITDA | -221.95M | -265.23M | -416.98M | -1.92B | -535.19M | -309.23M |
| Net Income | -281.40M | -340.19M | -433.81M | -1.96B | -555.84M | -319.58M |
Balance Sheet | ||||||
| Total Assets | 1.07B | 1.31B | 1.39B | 1.71B | 1.45B | 1.49B |
| Cash, Cash Equivalents and Short-Term Investments | 626.38M | 789.16M | 876.15M | 1.27B | 1.08B | 1.38B |
| Total Debt | 274.17M | 317.53M | 320.94M | 243.75M | 54.13M | 26.53M |
| Total Liabilities | 362.48M | 405.08M | 418.51M | 357.76M | 2.69B | 2.29B |
| Stockholders Equity | 711.50M | 885.66M | 974.73M | 1.35B | -1.25B | -790.51M |
Cash Flow | ||||||
| Free Cash Flow | -231.46M | -302.97M | -468.66M | -437.23M | -371.50M | -185.76M |
| Operating Cash Flow | -226.70M | -290.09M | -442.98M | -381.31M | -236.19M | -159.88M |
| Investing Cash Flow | -20.06M | -20.28M | 316.07M | -203.58M | 462.06M | -410.65M |
| Financing Cash Flow | 192.04M | 193.03M | 37.84M | 588.32M | -10.25M | 480.76M |
Cutia Therapeutics Technical Analysis
Negative
4.59
Price Trends
1.24
Negative
1.95
Negative
3.28
Negative
Market Momentum
-0.15
Negative
33.25
Neutral
30.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2487, the sentiment is Negative. The current price of 4.59 is above the 20-day moving average (MA) of 0.78, above the 50-day MA of 1.24, and above the 200-day MA of 3.28, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 33.25 is Neutral, neither overbought nor oversold. The STOCH value of 30.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2487.
Cutia Therapeutics Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | HK$925.48M | -2.35 | -66.16% | ― | 67.48% | 43.84% | |
50 Neutral | HK$1.79B | 17.80 | 48.25% | ― | 88.38% | ― | |
44 Neutral | HK$259.84M | -0.74 | -35.24% | ― | 35.47% | 46.42% | |
43 Neutral | HK$1.47B | -6.85 | -41.81% | ― | ― | -4.24% | |
43 Neutral | HK$327.59M | -1.65 | -27.54% | ― | 215.14% | 40.49% | |
42 Neutral | HK$463.21M | -4.83 | 133.13% | ― | -100.00% | 30.94% |
* General Sector Average
HK:2487
Cutia Therapeutics
0.69
-6.80
-90.79%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.22
-1.82
-45.05%
HK:2181
Mabpharm Limited
0.44
-0.09
-16.35%
HK:2257
Sirnaomics Ltd.
4.13
-5.64
-57.73%
HK:3681
SinoMab Bioscience Ltd.
1.07
-0.70
-39.55%
HK:6628
Transcenta Holding Limited
0.74
-2.32
-75.90%
Cutia Therapeutics Corporate Events
Cutia Therapeutics Expands Global Collaboration with Rejuven for Obesity-Targeted Drug CU-20401
Oct 20, 2026
Cutia Therapeutics has revised its collaboration with Rejuven Dermaceutical to extend their existing agreement on CU-20401, a recombinant mutant collagenase, beyond Asia to additional global territories. Under the supplemental deal, both companies...
Cutia Therapeutics Unveils Targeted Share Buyback to Signal Confidence
Sep 30, 2026
Cutia Therapeutics has announced a share repurchase program running from 2 October 2026 to 31 December 2026, authorizing buybacks of up to RMB30 million worth of shares on the open market under its existing mandate. The company will fund the repur...
Cutia Therapeutics Reshapes Board With CFO Exit and R&D Chief Promotion
Sep 30, 2026
Cutia Therapeutics announced that executive director and chief financial officer Huang Yuqing will step down effective 30 September 2026 to focus on personal commitments, with senior vice president Wu Jiaru taking over responsibility for strategic...
Cutia Wins Macao Approval for Topical Finasteride, Advancing Scalp Care Strategy
Sep 20, 2026
Cutia Therapeutics has secured marketing approval in Macao for its CU-40102 topical finasteride spray, indicated for the treatment of androgenetic alopecia, adding to earlier clearances in mainland China and Hong Kong. The product’s topical ...
Cutia Therapeutics’ Botulinum Toxin CU-20101 BLA Accepted by China’s NMPA
Sep 2, 2026
Cutia Therapeutics has announced that China’s National Medical Products Administration has accepted its Biologics License Application for CU-20101, a botulinum toxin type A injection targeting moderate to severe glabellar lines. The product ...
Cutia Therapeutics Accelerates Commercial Push in China’s Dermatology Market
Aug 31, 2026
Cutia Therapeutics reported solid progress in its interim business update for the six months to 30 June 2026, highlighting rapid commercialization of its flagship dermatology drugs. Since their launch in late October 2025, Finjuve and Amzeeq have ...
Cutia Therapeutics Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 19, 2026
Cutia Therapeutics has scheduled a board meeting for 31 August 2026 to review and approve the interim results for the six months ended 30 June 2026 and to authorize their publication. The board will also consider whether to recommend an interim di...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.